HUMA

– Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and cardiothoracic surgery markets – – Appointment strengthens commercial leadership as Symvess® (acellular tissue engineered vessel-tyod) market launch accelerates and pipeline advances toward planned BLA filing in dialysis – DURHAM, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the appointment of Jim Merc

- The Ministry of Health has set a 180-working-day review period for the MAA -  - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that its Marketing Authorization Application (MAA) seeking approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair has been accepted by the Israel Ministry of Health. The Ministry of Health has set a 180-working-day review period for the MAA

PRE 14A - Humacyte, Inc. (0001818382) (Filer)

10-K - Humacyte, Inc. (0001818382) (Filer)

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -  - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing Authorization Application with the Israel Ministry of Health - - U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access - - Conference call today at 8:00 am ET - DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a c

- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan

SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Fourth Quarter and Year End Financial Results and Corporate UpdateDateMarch 27, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)1

8-K - Humacyte, Inc. (0001818382) (Filer)

424B3 - Humacyte, Inc. (0001818382) (Filer)

DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals within the Kingdom of Saudi Arabia (KSA). The planned clinical evaluation program is to be conducted in parallel with ongoing negotiations with a KSA-based entity for establishment of a joint venture and license to commercialize Symvess within the country. Humacyte will provide

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The offering was led by a new life science dedicated investor and a long-only mutual fund  DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a securities purchase agreement with several new institutional investors for the purchase and sale of 25,000,000 shares of common

8-K - Humacyte, Inc. (0001818382) (Filer)

- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval -  - Preparation is underway for expansion of Symvess into other countries, including in the Middle East - DURHAM, N.C., March 17, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it submitted a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair. In response to surgeo

DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company's management team will be participating in the following investor conferences during the month of March. TD Cowen 46th Annual Healthcare ConferencePresentation: Wednesday March 4, 2026, 10:30-11:00 am Eastern TimeWebcast Link: Click Here Barclays 28th Annual Global Healthcare ConferencePresentation: Fireside Chat Time 1:00-1:25 pm Eastern TimeWebcast Link: Click Here About Humacyte Humacyte, Inc. (NASDAQ:HUMA) is developing a disruptive biotec

- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society -  - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - - Long-term durability results showed no dilatation nor narrowing of Symvess diameter out to 36 months - DURHAM, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of long-term data assessing the durability of Symvess in extremity arterial

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries. The FY2026 National Defense Authorization Act (NDAA), enacted in December 2025, stated in report language that DoD should "integrate FDA-approved breakthrough vascular repair technologies in traumatic extre

SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)

- Data is from comprehensive review of hospital charges and all-payer claims over five years -  - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte's Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage – DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the results of a five-year retrospective analysis of hospital charges, payer costs, and hea

- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel -  - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV™ or Symvess) for arterial trauma repair during the first quarter of 2026. The Compa

- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) -  - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma

8-K - Humacyte, Inc. (0001818382) (Filer)

424B5 - Humacyte, Inc. (0001818382) (Filer)

DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $77.5 million in principal amount of new financing. The credit agreement, which has a term of four years, includes an initial tranche of $40 million fully funded at close, and an additional two tranches of up to an aggregate of $37.5 million available to Humacyte, subject to the satisfaction of certain revenue, regulatory appro

8-K - Humacyte, Inc. (0001818382) (Filer)